Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNE PHARMACEUTICALS, INC.

(IMNPQ)
SummaryQuotesChartsNewsCompany 
Business Summary
Immune Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology. It operates though acquiring, developing and commercializing prescription drug products. Its lead product is bertilimumab, which is a fully human, anti-eotaxin-1, a regulator of immuno-inflammation. The Company is developing NanoCyclo, which is a nano-encapsulated formulation of cyclosporine-A for the treatment of atopic dermatitis and psoriasis. The CompanyÔÇÖs oncology portfolio includes Ceplene, which a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Number of employees : 7 people.
Managers
Name Title Age Since
Adeel Ahmed-Daudpota President & Chief Executive Officer 34 2021
Devin J. Shaw Chief Financial Officer 34 2021
John Zhang, Dr. Vice President-Research & Development - 2017
John A. Neczesny Independent Director 57 2016
Jeffrey Paley, Dr. Independent Director 53 2016
John P. Clark Secretary & Controller 49 2017
Members of the board
Name Title Age Since
David Sidransky, Dr. Director 60 2013
Daniel Kazado Director 56 2016
John A. Neczesny Independent Director 57 2016
Jeffrey Paley, Dr. Independent Director 53 2016
Anthony S. Fiorino, Dr. Director 53 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 172,878,093 172,878,093 100.0% 0 0.0% 100.0%
Stock B 0 3,713 0 0.0% 0 0.0%
Shareholders
NameEquities%
Heights Capital Management, Inc. 251,029 0.14%
Barclays Capital, Inc. 187,059 0.10%
Renaissance Technologies LLC 138,205 0.076%
The Vanguard Group, Inc. 136,841 0.075%
Edmond de Rothschild (Suisse) SA (Private Banking) 86,325 0.047%
Hudson Bay Capital Management LP 64,159 0.035%
Anson Funds Management LP 41,935 0.023%
Credit Suisse Securities (USA) LLC (Broker) 38,399 0.021%
Intellectus Partners LLC 31,082 0.017%
Goldman Sachs & Co. LLC (Private Banking) 28,405 0.016%
Company contact information
Immune Pharmaceuticals, Inc.
1 Bridge Plaza North
Suite 270
Englewood Cliffs, NJ 07024

Phone : +1.201.464.2677
Web : http://www.immunepharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Immune Pharmaceuticals, Inc.
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
IMMUNE PHARMACEUTICALS, INC.23.08%0
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992
NOVO NORDISK A/S-13.80%219 759
MERCK & CO., INC.6.39%205 965
NOVARTIS AG2.27%200 350
ASTRAZENECA PLC0.56%183 633
BRISTOL-MYERS SQUIBB COMPANY4.07%144 033
AMGEN INC.4.62%131 708
SANOFI3.93%130 951
GLAXOSMITHKLINE PLC5.89%116 252
BAYER AG10.77%57 955
CHUGAI PHARMACEUTICAL CO., LTD-0.05%53 569
JIANGSU HENGRUI MEDICINE CO., LTD.-8.87%46 341
TAKEDA PHARMACEUTICAL COMPANY LIMITED7.17%45 702
DAIICHI SANKYO CO., LTD.-9.66%44 204
ASTELLAS PHARMA INC.3.07%31 177
YUNNAN BAIYAO GROUP CO.,LTD-2.08%20 688